These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36907574)

  • 21. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    Liao C; Liang X; Zhang X; Li Y
    PLoS One; 2023; 18(8):e0289616. PubMed ID: 37616255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
    Dai Y; He H; Li S; Yang L; Wang X; Liu Z; An Z
    Front Endocrinol (Lausanne); 2020; 11():622589. PubMed ID: 33664710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis.
    Rezaei S; Tabrizi R; Nowrouzi-Sohrabi P; Jalali M; Atkin SL; Al-Rasadi K; Jamialahmadi T; Sahebkar A
    Can J Gastroenterol Hepatol; 2021; 2021():8936865. PubMed ID: 34805029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
    Deng M; Wen Y; Yan J; Fan Y; Wang Z; Zhang R; Ren L; Ba Y; Wang H; Lu Q; Fan H
    BMC Med; 2023 Nov; 21(1):447. PubMed ID: 37974258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis.
    Huang YZ; Yang GY; Wang C; Chen XY; Zhang LL
    World J Diabetes; 2021 Sep; 12(9):1576-1586. PubMed ID: 34630909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
    Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
    Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
    Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
    Yan H; Huang C; Shen X; Li J; Zhou S; Li W
    Front Endocrinol (Lausanne); 2022; 13():923606. PubMed ID: 35909522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1.
    Yin YH; Sang LX; Chang B
    World J Gastroenterol; 2023 Dec; 29(48):6235-6238. PubMed ID: 38186863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
    Barritt AS; Marshman E; Noureddin M
    Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis.
    Jianping W; Xuelian Z; Anjiang W; Haiying X
    J Clin Gastroenterol; 2021 Aug; 55(7):586-593. PubMed ID: 34039937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.
    Yuan X; Gao Z; Hao Z; Ma H; Duan K; Yang C
    Medicine (Baltimore); 2023 Oct; 102(43):e35739. PubMed ID: 37904378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Fan S; Shi X; Yao J; Zhong M; Feng P
    Rev Esp Enferm Dig; 2020 Aug; 112(8):627-635. PubMed ID: 32496108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety.
    Mills EP; Brown KPD; Smith JD; Vang PW; Trotta K
    Ther Adv Endocrinol Metab; 2018 Jan; 9(1):15-28. PubMed ID: 29344336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
    Lombardi R; Onali S; Thorburn D; Davidson BR; Gurusamy KS; Tsochatzis E
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011640. PubMed ID: 28358980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.
    Ma H; Lin YH; Dai LZ; Lin CS; Huang Y; Liu SY
    BMJ Open; 2023 Mar; 13(3):e061807. PubMed ID: 36882248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.